Last reviewed · How we verify
Rosuvastatin or atorvastatin or simvastatin and clopidogrel — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Rosuvastatin or atorvastatin or simvastatin and clopidogrel (Rosuvastatin or atorvastatin or simvastatin and clopidogrel) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rosuvastatin or atorvastatin or simvastatin and clopidogrel TARGET | Rosuvastatin or atorvastatin or simvastatin and clopidogrel | AstraZeneca | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel CI watch — RSS
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel CI watch — Atom
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel CI watch — JSON
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel alone — RSS
Cite this brief
Drug Landscape (2026). Rosuvastatin or atorvastatin or simvastatin and clopidogrel — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin-or-atorvastatin-or-simvastatin-and-clopidogrel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab